Dermatology CRO Market (By Service: Project Management/Clinical Supply Management, Data Management, Regulatory/Medical Affairs, Medical Writing, Clinical Monitoring, Quality Management/Assurance, Bio-statistics, Investigator Payments, Laboratory, Patient and Site Recruitment, Technology, Others; By Type: Drug Discovery, Preclinical, Clinical; By Phase Type: Phase I, Phase II, Phase III, Phase IV) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dermatology CRO Market
5.1. COVID-19 Landscape: Dermatology CRO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dermatology CRO Market, By Service
8.1. Dermatology CRO Market, by Service, 2023-2032
8.1.1 Project Management/Clinical Supply Management
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. Data Management
8.1.2.1. Market Revenue and Forecast (2021-2032)
8.1.3. Regulatory/Medical Affairs
8.1.3.1. Market Revenue and Forecast (2021-2032)
8.1.4. Regulatory/Medical Affairs
8.1.4.1. Market Revenue and Forecast (2021-2032)
8.1.5. Clinical Monitoring
8.1.5.1. Market Revenue and Forecast (2021-2032)
8.1.6. Quality Management/Assurance
8.1.6.1. Market Revenue and Forecast (2021-2032)
8.1.7. Bio-statistics
8.1.7.1. Market Revenue and Forecast (2021-2032)
8.1.8. Investigator Payments
8.1.8.1. Market Revenue and Forecast (2021-2032)
8.1.9. Laboratory
8.1.9.1. Market Revenue and Forecast (2021-2032)
8.1.10. Clinical Monitoring
8.1.10.1. Market Revenue and Forecast (2021-2032)
8.1.11. Technology
8.1.11.1. Market Revenue and Forecast (2021-2032)
8.1.12. Clinical Monitoring
8.1.12.1. Market Revenue and Forecast (2021-2032)
8.1.13. Others
8.1.13.1. Market Revenue and Forecast (2021-2032)
Chapter 9. Global Dermatology CRO Market, By Type
9.1. Dermatology CRO Market, by Type, 2023-2032
9.1.1. Drug Discovery
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. Preclinical
9.1.2.1. Market Revenue and Forecast (2021-2032)
9.1.3. Clinical
9.1.3.1. Market Revenue and Forecast (2021-2032)
Chapter 10. Global Dermatology CRO Market, By Phase Type
10.1. Dermatology CRO Market, by Phase Type, 2023-2032
10.1.1. Phase I
10.1.1.1. Market Revenue and Forecast (2021-2032)
10.1.2. Phase II
10.1.2.1. Market Revenue and Forecast (2021-2032)
10.1.3. Phase III
10.1.3.1. Market Revenue and Forecast (2021-2032)
10.1.4. Phase IV
10.1.4.1. Market Revenue and Forecast (2021-2032)
Chapter 11. Global Dermatology CRO Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Service (2021-2032)
11.1.2. Market Revenue and Forecast, by Type (2021-2032)
11.1.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service (2021-2032)
11.1.4.2. Market Revenue and Forecast, by Type (2021-2032)
11.1.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service (2021-2032)
11.1.5.2. Market Revenue and Forecast, by Type (2021-2032)
11.1.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service (2021-2032)
11.2.2. Market Revenue and Forecast, by Type (2021-2032)
11.2.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service (2021-2032)
11.2.4.2. Market Revenue and Forecast, by Type (2021-2032)
11.2.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service (2021-2032)
11.2.5.2. Market Revenue and Forecast, by Type (2021-2032)
11.2.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service (2021-2032)
11.2.6.2. Market Revenue and Forecast, by Type (2021-2032)
11.2.6.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service (2021-2032)
11.2.7.2. Market Revenue and Forecast, by Type (2021-2032)
11.2.7.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service (2021-2032)
11.3.2. Market Revenue and Forecast, by Type (2021-2032)
11.3.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service (2021-2032)
11.3.4.2. Market Revenue and Forecast, by Type (2021-2032)
11.3.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service (2021-2032)
11.3.5.2. Market Revenue and Forecast, by Type (2021-2032)
11.3.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service (2021-2032)
11.3.6.2. Market Revenue and Forecast, by Type (2021-2032)
11.3.6.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service (2021-2032)
11.3.7.2. Market Revenue and Forecast, by Type (2021-2032)
11.3.7.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service (2021-2032)
11.4.2. Market Revenue and Forecast, by Type (2021-2032)
11.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service (2021-2032)
11.4.4.2. Market Revenue and Forecast, by Type (2021-2032)
11.4.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service (2021-2032)
11.4.5.2. Market Revenue and Forecast, by Type (2021-2032)
11.4.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service (2021-2032)
11.4.6.2. Market Revenue and Forecast, by Type (2021-2032)
11.4.6.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service (2021-2032)
11.4.7.2. Market Revenue and Forecast, by Type (2021-2032)
11.4.7.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service (2021-2032)
11.5.2. Market Revenue and Forecast, by Type (2021-2032)
11.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service (2021-2032)
11.5.4.2. Market Revenue and Forecast, by Type (2021-2032)
11.5.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service (2021-2032)
11.5.5.2. Market Revenue and Forecast, by Type (2021-2032)
11.5.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)
Chapter 12. Company Profiles
12.1. IQVIA HOLDINGS INC.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Covance Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pharmaceutical Product Development, LLC (PPD)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Parexel International Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Charles River Laboratories International, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Icon, Plc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Medidata Solutions, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Syneos Health
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pharmaron
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GVK Biosciences Private Limited
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample